Market Place
Sourcing Support
FDA warns online vendors selling unapproved weight-loss drugs
18 Dec 2024 //
REUTERS
High-flying Eli Lilly plots $15B share buyback plan
11 Dec 2024 //
FIERCE PHARMA
BioAge scraps mid-stage trial of obesity drug, shares fall
09 Dec 2024 //
REUTERS
Lilly Invests $3B To Boost Wisconsin Plant For Obesity Drugs
07 Dec 2024 //
REUTERS
Lilly`s Zepbound Beats Wegovy In Weight Loss Trial: 20.2% Vs. 13.7%
05 Dec 2024 //
PR NEWSWIRE
England`s NICE to phase rollout for Lilly`s tirzepatide in obesity
05 Dec 2024 //
FIERCE PHARMA
Legal Challenge Over Lilly’s GLP-1 Shortages
26 Nov 2024 //
BIOSPACE
Lilly’s Tirzepatide Reduces Heart Failure Risk in HFpEF & Obesity
16 Nov 2024 //
PR NEWSWIRE
Eli Lilly`s weight-loss drug helps nearly 99% of patients remain diabetes-free
14 Nov 2024 //
REUTERS
Palatin Completes Enrollment in Bremelanotide Obesity Study
31 Oct 2024 //
PR NEWSWIRE
Lilly cuts revenue guidance as momentum stalls for tirzepatide
30 Oct 2024 //
FIERCE PHARMA
Eli Lilly gets nod to launch weight-loss drug in Hong Kong
28 Oct 2024 //
REUTERS
FDA reviews decision to put Lilly`s tirzepatide on shortage list
14 Oct 2024 //
FIERCE PHARMA
In China, Lilly plans $200M expansion to make tirzepatide meds
11 Oct 2024 //
FIERCE PHARMA
Lexaria`s GLP-1 Human Pilot Study #3 Begins Dosing
09 Oct 2024 //
ACCESSWIRE
Minus one of its GLP-1 cash cows, compounding group sues FDA
08 Oct 2024 //
FIERCE PHARMA
MangoRx Launches Oral Tirzepatide GLP-1 For Weight Loss
03 Oct 2024 //
GLOBENEWSWIRE
US FDA says Lilly`s weight-loss drug no longer in shortage
03 Oct 2024 //
REUTERS
Enforcement Report - Week of September 11, 2024
11 Sep 2024 //
FDA
From the Neuland Reading Room: Peptide Trends in 2024
02 Sep 2024 //
PRESS RELEASE
Palatin Doses First Patient In Bremelanotide-Tirzepatide Obesity Trial
23 Aug 2024 //
PR NEWSWIRE
Lilly’s Tirzepatide Cuts Type 2 Diabetes Risk by 94% in Overweight Adults
21 Aug 2024 //
BIOSPACE
Lilly Catalyze360 looks to connect with emerging biotechs across `all areas`
20 Aug 2024 //
FIERCE BIOTECH
Eli Lilly Raises Sales Guidance By $3B As Mounjaro, Zepbound Recover
08 Aug 2024 //
FIERCE PHARMA
Lilly`s Tirzepatide Shows Benefit In Heart Failure With Obesity
02 Aug 2024 //
PR NEWSWIRE
BioAge Doses First Patient In STRIDES Phase 2 Obesity Trial
29 Jul 2024 //
BUSINESSWIRE
Eli Lilly`s weight loss drug tirzepatide gets approval in China
19 Jul 2024 //
REUTERS
Eli Lilly vaults Simone Biles to head of Mounjaro ad campaign
16 Jul 2024 //
FIERCE PHARMA
India panel urges drug regulator to approve Lilly`s obesity drug Mounjaro
02 Jul 2024 //
REUTERS
Terns’ ex-MASH drug cuts fat, not muscle or food intake, in GLP-1 combo in mice
25 Jun 2024 //
FIERCE BIOTECH
Novo Nordisk`s Wegovy weight-loss drug approved in China
25 Jun 2024 //
REUTERS
Weight Gain Restarts When Wegovy Stops; Could GLP-1 Gene Therapy Help?
24 Jun 2024 //
FIERCE BIOTECH
Doctors must keep Ozempic prescriptions in check, Danish regulator says
24 Jun 2024 //
REUTERS
Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients
24 Jun 2024 //
REUTERS
WHO issues warnings on fake copies of Novo Nordisk`s weight-loss drugs
21 Jun 2024 //
NCBNEWS
Ozempic frenzy lures rich Indians to brave the gray market
18 Jun 2024 //
ECONOMICTIMES
Eli Lilly exec says seeing out of pocket payments for obesity drug in US
11 Jun 2024 //
REUTERS
Lilly`s tirzepatide was superior to placebo for MASH, improves fibrosis
07 Jun 2024 //
PR NEWSWIRE
Lilly pads tirzepatide`s MASH win with detailed fibrosis data
06 Jun 2024 //
FIERCE PHARMA
Enforcement Report - Week of June 5, 2024
05 Jun 2024 //
FDA
Britain considers offering Lilly weight-loss drug on better terms than Wegovy
04 Jun 2024 //
REUTERS
Lilly wins NICE backing for tirzepatide in obesity
04 Jun 2024 //
FIERCE PHARMA
Henry Meds: Oral Tirzepatide Tablets For Weight Loss Treatment
28 May 2024 //
BUSINESSWIRE
Lilly invests further $5.3 bln in new Indiana site as obesity drug demand soars
25 May 2024 //
REUTERS
Lilly $9B Indiana Site Boost: Tirzepatide Api Capacity Manufacturing Investment
24 May 2024 //
PR NEWSWIRE
Eli Lilly settles with med spa selling fake Mounjaro, Zepbound
16 May 2024 //
FIERCE PHARMA
India`s Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
11 May 2024 //
REUTERS
Back Amgen Soars After CEO Gives Update on Experimental Obesity Drug
03 May 2024 //
LIVEMINT
Palatin Gets IND For Bremelanotide+Tirzepatide Obesity Combo
02 May 2024 //
PR NEWSWIRE
Eli Lilly`s weight-loss drug succeeds in trials with sleep apnea patients
18 Apr 2024 //
REUTERS
Tirzepatide Reduces Sleep Apnea Severity in Obese Adults
17 Apr 2024 //
PR NEWSWIRE
Most of Lilly`s Mounjaro and Zepbound doses in limited supply, FDA says
17 Apr 2024 //
REUTERS
Eli Lilly loses case against Florida compounding pharmacy
11 Apr 2024 //
ENDPTS
AMRA Medical Shows Tirzepatide`s Effect on Fat Biomarkers
10 Apr 2024 //
BUSINESSWIRE
Lilly`s weight-loss drug Zepbound to face supply crunch April-end, US FDA says
03 Apr 2024 //
REUTERS
Demand for Lilly`s Zepbound triggers US supply constraints
30 Mar 2024 //
FIERCE PHARMA
Lilly drug Zepbound new US prescriptions surpass Wegovy for first time
15 Mar 2024 //
REUTERS
Lilly partners with Amazon to deliver Zepbound and other drugs
13 Mar 2024 //
REUTERS
CBO hints that Medicare may cover obesity drugs for cardiovascular benefits
12 Mar 2024 //
ENDPTS
Lilly flags impurity concerns in fake versions of GLP-1 drugs
08 Mar 2024 //
FIERCE PHARMA
